864070-43-9

Usage

Uses

Used in Pharmaceutical Industry:
Empagliflozin (R)-Isomer is used as a pharmaceutical agent for improving glycemic control and managing features of metabolic syndrome in diabetic rats. Its selective SGLT-2 inhibition helps regulate blood sugar levels and alleviate symptoms associated with diabetes.

Upstream product

• 864070-37-1 (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-hydroxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 112052-11-6 toluene-4-sulfonic acid (S)-(tetrahydrofuran-3-yl)ester 
• 915095-98-6 1-chloro-4-(2,3,4,6-tetra-O-acetyl-D-glucopyranos-1-yl)-2-(4-(R)-tetrahydrofuran-3-yloxy-benzyl)-benzene 
• 219823-47-9 (R)-tetrahydrofuran-3-yl 4-methylbenzenesulfonate 
• 915095-96-4 methyl-1-C-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucopyranoside 
• 915095-94-2 (3S)-3-[4-[(2-chloro-5-iodophenyl)methyl]phenoxy]tetrahydrofuran 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 1198-69-2 D-glucono-1,4-lactone 
• 108-95-2 phenol 
• 637-87-6 1-Chloro-4-iodobenzene 
• 13096-62-3 (3R,4S,5R,6R)-3,4,5-tris(benzyloxy)-6-((benzyloxy)methyl)tetrahydro-2H-pyran-2-one 
• 915095-89-5 (S)-4-bromo-1-chloro-2-(4-tetrahydrofuran-3-yloxy-benzyl)benzene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 

Relevant academic research and scientific papers

Preparation method of SGLT-2 inhibitor and intermediate

The invention discloses a preparation method of an SGLT-2 inhibitor and an intermediate. The method comprises the following steps: (1) reacting a compound A with chlorosilane under the action of an acid-binding agent to generate a compound B; (2) mixing the compound B and a compound C to obtain a compound D; and (3) reacting the compound D with a reducing agent and a catalyst to obtain the SGLT-2 inhibitor compound.

IMPROVED PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN AND ITS CRYSTALLINE POLYMORPH

The present invention relates to an improved method for the production of Empagliflozin formula (I). The invention further relates to the preparation of a crystalline form of Empagliflozin and its particle size having a coarser particle or a D50 equal to or greater than 60 μm and a D90 equal to or greater than 180 μm. (I)

New Glyflozin Synthesis Method in a Continuous Reaction Process

The present invention relates to a method for synthesizing glyflozin. Provided is a synthesis method including: a first step of reacting a stream including an initial reactant and a lactone, and a stream including n-butyllithium to produce a first product; and a second step of reacting a stream including the first product and a stream including a Lewis acid to produce a second product.

SELECTIVE VALORIZATION OF BIOMASS SUGARS

Disclosed are methods of forming an epimer or a dehydrated isomer of a pyranose monosaccharide or a pyranose saccharide residue in an oligosaccharide or a glycoside.

Synthetic method of empagliflozin

The invention discloses a synthesis method of empagliflozin. According to the method, (S)-3-(4-(5-bromo-2-chlorobenzyl) phenoxy) tetrahydrofuran is adopted as a starting raw material and is coupled with 2, 3, 4, 6-tetrabenzyl-D-glucopyranosyl-1, 5-lactone under the catalysis of Pd2 (dba) 3 and the combined action of p-toluenesulfonhydrazide, Xphos and lithium tert-butoxide to generate an intermediate I, double bonds of the intermediate I are subjected to hydrogenation reduction through raney nickel, meanwhile, debenzylation is conducted, and the empagliflozin is obtained. The method does not need butyl lithium, Grignard reagent and other dangerous materials, has the advantages of short reaction route, simple reaction and post-treatment, high safety, few side reactions, high product yield and high purity, and is especially suitable for industrial production.

Synthetic method of empagliflozin

The invention belongs to the technical field of raw material medicine preparation, and relates to a synthetic method of an SGLT-2 inhibitor empagliflozin, which comprises the following steps: 1) taking glucose as an initial raw material, and preparing an active intermediate 3 through full acylation, selective hydrolysis and esterification; 2) reacting the intermediate 3 with chlorobenzene under the catalysis of boron trifluoride/diethyl ether to generate an intermediate 4, and reacting the intermediate 4 with paraformaldehyde and phenoxy tetrahydrofuran to generate an intermediate 5; and 3) removing the protecting group under the action of alkali to obtain the final product empagliflozin. The method is simple to operate, low-temperature reaction in the prior art is avoided, and the purity of the obtained product is higher.

Preparation method of glucopyranosyl substituted benzyl benzene derivative and intermediate thereof

The invention relates to a preparation method of a glucopyranosyl substituted benzyl benzene derivative and an intermediate thereof, and a method for preparing a compound represented by a formula (I),wherein the group R is defined in claim 1. The method is simple to operate, high in product yield, good in selectivity and suitable for industrial production. The present invention relates to theintermediate obtained in the method.

Preparation and refining method of high-purity enzagliflozin (by machine translation)

Firstly, under the condition of ensuring the yield of the crude product, the purity of, the crude product is improved to the purity of the, crude product, so, that the refining and purifying times; are obviously reduced and further, optimized and refined. (by machine translation)

Synthetic method of empagliflozin

The invention provides a brand-new synthesis process of empagliflozin. According to the process, a boric acid ester is used for halogen removal, and specific reaction conditions are combined, so thatempagliflozin can be prepared with high yield and simplicity and convenience in operation. The synthesis method of empagliflozin has the advantages of mild reaction conditions, high total yield, few side reactions and convenience in operation, thereby being beneficial to industrial production and cost control.